Mucormycosis, Epidemiology

Last updated: 2021 Dec 7
Total hit(s): 8
Select item(s)
Key Findings
Comments
(You can add your comments too!)
Original Article
(hover to see details)
The most common predisposing factors for mucormycosis were poor glycaemic management, moderately severe pneumonia, mechanical ventilation, and failure to receive the COVID19 vaccine. To overcome the high mortality rate that comes with mucormycosis infection high index of suspicion is required to ensure timely diagnosis and appropriate treatment in high-risk populations.
✍
 		34255907
(Mycoses)
PMID
34255907
Date of Publishing: 2021 Jul 13
Title Mucormycosis and COVID-19: An epidemic within a pandemic in India
Author(s) nameSelarka L, Sharma S et al.
Journal Mycoses
Impact factor
3.05
Citation count: 32
Date of Entry 2021 Dec 7

In a group of 70 COVID-19 Associated mucormycosis (CAM) patients, 93% had at least one risk fator. Diabetes mellitus (70%) and steroid use (70%) for COVID-19 disease were the most common risk factors. 20 days was the median duration between onset of COVID-19 symptoms and onset of CAM symptoms. Only 5 out of 70 patients (7.1%) had no comorbidities, were using immunosuppressants (including steroids), or had recently had their blood glucose levels raised.
✍
 		34254132
(QJM)
PMID
34254132
Date of Publishing: 2021 Jul 12
Title COVID-19-associated mucormycosis presenting to the Emergency Departmentan observational study of 70 patients
Author(s) nameRamaswami A, Sahu AK et al.
Journal QJM
Impact factor
1.35
Citation count: 9
Date of Entry 2021 Dec 7

Long-term use of cloth or surgical masks, as well as extensive nasopharyngeal swab testing, have been identified as novel risk factors for COVID associated Mucormycosis (CAM), in addition to the more well-known diabetes and systemic corticosteroid use. To avoid mucormycosis, judicious administration of steroids and strict glycemic control are essential. Using clean masks, preferring N95 masks if available, and limiting swab testing following a COVID-19 diagnosis may help to lower the risk of CAM.
✍
 		Pre-print (medRXiv)
Title Novel risk factors for Coronavirus disease-associated mucormycosis (CAM): a case control study during the outbreak in India
Impact factor
N/A
Date of Entry 2021 Dec 7

Twelve week Covid associated mucormycosis (CAM) mortality rate in France (88%) was observed to be higher than the mortality rate in India (40-50%) which could be due to poorer prognosis.
✍
 		Pre-print (medRXiv)
Title High mortality of COVID-19 associated mucormycosis (CAM) in France: a nationwide retrospective study
Impact factor
N/A
Date of Entry 2021 Dec 7

Instances of mucormycosis of the eye have increased in post-COVID 19 patients especially in those with pre-existing comorbidity. Diabetes is the most common predisposing factor. Systemic antifungal medicine and surgical removal of affected tissues have been found to be effective in the treatment of mucormycosis. For post-COVID-19 patients, immune-suppression along with pre-existing comorbidity may result in secondary infections.
✍
 		34414101
(Indian J Otolaryngol Head Neck Surg)
PMID
34414101
Date of Publishing: 2021 Aug 15
Title Epidemiology, Clinical Features and Management of Rhino Orbital Mucormycosis in Post COVID 19 Patients
Author(s) nameDesai EJ, Pandya A et al.
Journal Indian J Otolaryngol Head Neck Surg
Impact factor
- n/a -
Citation count: 2
Date of Entry 2021 Oct 30

The occurence if rhino orbital cerebral mucormycosis (ROCM) has increased dramatically with the rise in COVID-19 cases. Diabetes Mellitus (DM) and corticosteroids are the most important risk factors for COVID-19-associated ROCM. The most common risk factor for the development of ROCM was the use of corticosteroids, which increased in proportion to the severity of COVID-19. DM has been identified as an independent risk factor for mucormycosis.
✍
 		34156034
(Indian J Ophthalmol)
PMID
34156034
Date of Publishing: 2021 Jul
Title Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2826 patients in India Collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC), Report 1
Author(s) nameSen M, Honavar SG et al.
Journal Indian J Ophthalmol
Impact factor
0.93
Citation count: 68
Date of Entry 2021 Oct 30

In the September-December 2019 study period, there was a 2.1-fold increase in mucormycosis. The most frequent underlying condition among COVID-19 associated mucormycosis (CAM) and non-CAM patients was uncontrolled diabetes mellitus. In 32.6% of CAM patients, COVID-19 was the only underlying illness. COVID-19-related hypoxemia and incorrect glucocorticoid use were both linked to CAM. Majority of the patients with CAM had hypoxia and required ICU admission. The most common mucormycosis location was the rhino-orbital area (58.2%), followed by rhino-orbital-cerebral, pulmonary, and other sites.
✍
 		34087089
(Emerg Infect Dis)
PMID
34087089
Date of Publishing: 2021 Jun 4
Title Multicenter Epidemiologic Study of Coronavirus Disease-Associated Mucormycosis, India
Author(s) namePatel A, Agarwal R et al.
Journal Emerg Infect Dis
Impact factor
6.81
Citation count: 89
Date of Entry 2021 Sep 28

At 12 weeks, the case-fatality rate for mucormycosis was 45.7%, with no difference between COVID-19-associated mucormycosis (CAM) and non-CAM patients. Age, involvement of the rhino-orbital-cerebral system, and admission to an intensive care unit were all linked to higher fatality rates; however, periodic antifungal treatment improved mucormycosis survival. In both groups, liposomal amphotericin B was the most commonly utilised antifungal agent. When compared to the non-CAM group, the utilisation of liposomal amphotericin B was substantially lower in the CAM group (72.7% Vs 84%). Combined medical and surgical management was similar between both the groups.
✍
 		34087089
(Emerg Infect Dis)
PMID
34087089
Date of Publishing: 2021 Jun 4
Title Multicenter Epidemiologic Study of Coronavirus Disease-Associated Mucormycosis, India
Author(s) namePatel A, Agarwal R et al.
Journal Emerg Infect Dis
Impact factor
6.81
Citation count: 89
Date of Entry 2021 Sep 28